Trial Profile
Study of IO#2.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Anti GITR immunotherapy OncoMed (Primary)
- Indications Cancer
- Focus Adverse reactions
- 10 Jan 2017 New trial record
- 31 Dec 2016 According to an OncoMed Pharmaceuticals media release, company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.